Markets:

Overview

News

Currencies

International

Treasuries

Galapagos NV - American Depositary Shares (NQ:GLPG)

29.59 +0.17 (+0.58%)

Streaming Delayed Price Updated: 12:47 PM EDT, Apr 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Galapagos NV - American Depositary Shares

< Previous 1 2 3 4 Next >

Gilead Sciences Acquires Ouro Medicines for $2.2 Billion to Lead 'Immune Reset' Revolution

March 31, 2026

In a move that signals a decisive shift in the treatment of chronic autoimmune conditions, Gilead Sciences (NASDAQ:GILD) announced on March 23, 2026, its definitive agreement to acquire Ouro Medicines...

Via MarketMinute

Galapagos Stock Rises After Hours On Starting To Wind Down Cell Therapy Activities, Workforce Reduction ↗

January 05, 2026

Via Stocktwits

Aurinia Raises Guidance and Shares Are Surging— Is This Why a Major Investor Just Boosted Its Stake? ↗

December 02, 2025

A top life sciences investor is doubling down as Aurinia’s flagship therapy gains momentum—here’s what long-term shareholders should watch next.

Via The Motley Fool

Earnings Scheduled For November 5, 2025 ↗

November 05, 2025

Via Benzinga

Earnings Scheduled For July 23, 2025 ↗

July 23, 2025

Via Benzinga

Earnings Scheduled For April 23, 2025 ↗

April 23, 2025

Via Benzinga

Uncovering Potential: Galapagos's Earnings Preview ↗

April 22, 2025

Via Benzinga

Earnings Scheduled For February 12, 2025 ↗

February 12, 2025

Via Benzinga

These stocks that are showing activity before the opening bell on Tuesday. ↗

October 21, 2025

The US market session of Tuesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.

Via Chartmill

PACCAR Posts Downbeat Earnings, Joins Neuphoria Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

October 21, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

October 21, 2025

Via Benzinga

Why Crown Holdings Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket ↗

October 21, 2025

Via Benzinga

Adaptimmune Plunges After Announcing Nasdaq Delisting Amidst Compliance Failures and Cost-Cutting Measures

October 20, 2025

Adaptimmune Therapeutics plc (NASDAQ: ADAP) has sent shockwaves through the biotechnology sector with its announcement on October 20, 2025, of a voluntary delisting of its American Depositary Shares...

Via MarketMinute

Tesla Posts Downbeat Earnings, Joins Community Health Systems, Chipotle Mexican Grill And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

July 24, 2025

Via Benzinga

Get insights into the top gainers and losers of Thursday's pre-market session. ↗

July 24, 2025

Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top gainers and losers in today's pre-market session.

Via Chartmill

Why Alphabet Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket ↗

July 24, 2025

Via Benzinga

Galapagos Announces CFO Exit With No Successor Named Yet: Retail’s Disappointed ↗

April 15, 2025

The company expects to announce a new CFO “in the coming months.”

Via Stocktwits

Topics Earnings

Galapagos Unveils 2025 Split To Accelerate Innovation, Sharpen Strategic Focus ↗

January 08, 2025

Galapagos NV plans to split into two entities by mid-2025, focusing on oncology cell therapy and innovative medicines, with €2.45 billion allocated to SpinCo's pipeline.

Via Benzinga

Why Trip.com Group Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket ↗

August 27, 2024

Via Benzinga

Major Investor Says Galapagos Is 'Undervalued,' Plans To Push On Company's 'Performance' And 'Strategic Opportunities' ↗

August 26, 2024

Galapagos stock rises as EcoR1 Capital discloses a 9.9% stake and plans to engage on business and governance. Investor sees shares as deeply undervalued despite challenges, with new focus on CAR-T...

Via Benzinga

Galapagos Surges On An FDA Win For Its Rival To Gilead, Novartis; But There Are Some Caveats ↗

August 26, 2024

The company is gearing up to rival giants Gilead and Novartis with a potentially decentralized CAR-T process.

Via Investor's Business Daily

Galapagos, XPeng, CorMedix And Other Big Stocks Moving Higher On Monday ↗

August 26, 2024

Via Benzinga

Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket ↗

August 26, 2024

Via Benzinga

FDA Approves Adaptimmune Therapeutics' Engineered Cell Therapy As First For Solid Tumor And New Therapy For Rare Soft Tissue Cancer In Over A Decade ↗

August 02, 2024

FDA approves Adaptimmune Therapeutics' Tecelra for unresectable or metastatic synovial sarcoma, a rare cancer near large joints. Tecelra, the first engineered cell therapy for solid tumors in the U.S.,...

Via Benzinga

GLPG Stock Earnings: Galapagos Beats EPS, Beats Revenue for Q2 2024 ↗

August 01, 2024

GLPG stock results show that Galapagos beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

GLPG Stock Earnings: Galapagos Beats EPS, Misses Revenue for Q1 2024 ↗

June 25, 2024

GLPG stock results show that Galapagos beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

Via InvestorPlace

Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications

May 30, 2024

Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell...

Via Newsfile

Galapagos Downgraded, Pharma Firm Faces Uphill Battle With Slow Pipeline Progress: Analyst ↗

April 01, 2024

BofA Securities downgrades Galapagos to underperform due to limited near-term catalysts and competitive challenges in crowded markets.

Via Benzinga

Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline

February 22, 2024

From Frontier Medicines

Via GlobeNewswire

European Drugmaker Galapagos Collaborates With Biotech BridGene Biosciences To Develop Cancer Treatments ↗

January 03, 2024

On Wednesday, BridGene Biosciences Inc. announced a strategic collaboration and licensing agreement with Galapagos NV (NASDAQ: GLPG).

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.